The Efficacy and Safety of Tirofiban Enhanced Antiplatelet Therapy in the Treatment of Ruptured Intracranial Aneurysms With Stent
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 622 participants.
Also called NCT07818083
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 622 participants
- Registry
-
NCT07818083
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07818083. Randomized; triple masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2028-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy and Safety of Tirofiban Enhanced Antiplatelet Therapy in the Treatment of Ruptured Intracranial Aneurysms With Stent
- Acronym
- TEARIAS
- Condition
- Ruptured Intracranial Aneurysms
- Condition
- Subarachnoid Hemorrhage, Aneurysmal
- Intervention (Drug)
- Tirofiban+Oral Dual Antiplatelet Therapy
- Intervention (Drug)
- Dual Antiplatelet Therapy plus Normal Saline
- Lead sponsor
- First Affiliated Hospital of Fujian Medical University
Record details
- Record id
cardio:ct-nct07818083- Content hash
76cfe03d82f87f2629f80afff125dfd66eab1b4de0fbee31524bae4a42aa5dea